Comparing Diplomat Pharmacy (DPLO) and The Competition
Diplomat Pharmacy (NYSE: DPLO) is one of 23 publicly-traded companies in the “Food Retail & Distribution” industry, but how does it weigh in compared to its rivals? We will compare Diplomat Pharmacy to similar businesses based on the strength of its risk, profitability, earnings, dividends, institutional ownership, valuation and analyst recommendations.
Earnings & Valuation
This table compares Diplomat Pharmacy and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Diplomat Pharmacy||$4.53 billion||$70.47 million||126.59|
|Diplomat Pharmacy Competitors||$21.39 billion||$989.23 million||39.13|
Diplomat Pharmacy’s rivals have higher revenue and earnings than Diplomat Pharmacy. Diplomat Pharmacy is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current ratings for Diplomat Pharmacy and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Diplomat Pharmacy Competitors||644||1344||1391||22||2.23|
Diplomat Pharmacy currently has a consensus target price of $19.16, indicating a potential downside of 10.98%. As a group, “Food Retail & Distribution” companies have a potential upside of 4.06%. Given Diplomat Pharmacy’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Diplomat Pharmacy has less favorable growth aspects than its rivals.
Institutional & Insider Ownership
69.9% of Diplomat Pharmacy shares are held by institutional investors. Comparatively, 56.2% of shares of all “Food Retail & Distribution” companies are held by institutional investors. 30.2% of Diplomat Pharmacy shares are held by insiders. Comparatively, 17.1% of shares of all “Food Retail & Distribution” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Diplomat Pharmacy and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Diplomat Pharmacy Competitors||0.47%||32.27%||3.63%|
Volatility and Risk
Diplomat Pharmacy has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Diplomat Pharmacy’s rivals have a beta of 0.93, suggesting that their average share price is 7% less volatile than the S&P 500.
Diplomat Pharmacy rivals beat Diplomat Pharmacy on 10 of the 13 factors compared.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc. (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Company offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company’s patient care system is used to coordinate and track patient adherence and safety.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.